The CPT Editorial Panel (the Panel) has approved a vaccine product code (91310) and its associated vaccine administration code (0104A) for the new Sanofi Pasteur vaccine product to address severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease 2019 [COVID-19]) in adult patients aged 18 years and older. In addition to the new Sanofi Pasteur codes, the Panel also approved a new Pfizer booster dose vaccine administration code (0074A) that is to be reported with vaccine product code 91307 when a booster dose of the Pfizer vaccine is administered to a pediatric patient aged 5 through 11 years. These three codes will become effective upon receiving emergency use authorization (EUA) from the Food and Drug Administration (FDA).
Read also: New COVID update for Vaccines Codes
Immunization Administration for Vaccines/Toxoids
0074A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL
dosage, diluent reconstituted, trissucrose formulation; booster dose
0104A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion; booster dose
(Report 0104A for the administration of vaccine 91310)
91310 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use
(Report 91310 with administration code 0104A)
Code 91310 describes Sanofi Pasteur’s COVID-19 vaccine product for adult patients aged 18 years and older. This vaccine uses a 5 mcg/0.5 mL dosage concentration, and it will be used only as a booster dose for patients who have already completed a primary series of any approved COVID-19 vaccine (Pfizer, Moderna, or Janssen [Johnson & Johnson]). Code 0104A is the new vaccine booster dose administration code to be reported with Sanofi Pasteur’s COVID-19 vaccine product (91310). Note that there will be no primary series available for the Sanofi COVID-19 vaccine.
Code 0074A is the new vaccine booster dose administration code to be reported with Pfizer’s already established vaccine product code (91307) for patients aged 5 through 11 years of age.
Note that vaccine administration code 0104A is only intended to be reported with vaccine product code 91310 and administration code 0074A is only intended to be reported with vaccine product code 91307.
Reference:
https://www.ama-assn.org/system/files/cpt-assistant-guide-coronavirus-april-2022.pdf